Skip to content

Study · Randomized controlled trial · n = 40 · 2021

6 results

Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial.

Siriwattanasit N, Satirapoj B, Supasyndh O

BMC nephrology26 Jun 2021Cited by 15 (Europe PMC)

PMID34174842 (opens in a new tab)PMCIDPMC8235831 (opens in a new tab)DOI10.1186/s12882-021-02434-7 (opens in a new tab)PepBankPUB-34174842
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

BackgroundActivation of the transforming growth factor beta (TGF-β) pathway is a significant contributor to the pathogenesis of diabetic nephropathy. Carnosine is a dipeptide that can inhibit TGF-β synthesis. We tested the hypothesis that carnosine supplement added to standard therapy will result in reduced urinary TGF-β levels among patients with diabetic nephropathy.MethodsWe randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks. Urinary TGF-β level was determined using ELISA, urine albumin was ascertained by immunonephelometric assay, and renal function and metabolic profiles were determined at baseline and during 12 weeks of active treatment. Primary outcome was decrease in urinary levels of TGF-β.ResultsThe 2 groups were comparable for baseline characteristics, blood pressure, urine albumin, urine TGF-β and renal function measurements. Urinary TGF-β significantly decreased with carnosine supplement (- 17.8% of the baseline values), whereas it tended to increase with placebo (+ 16.9% of the baseline values) (between-group difference P < 0.05). However, blood urea nitrogen, serum creatinine, glomerular filtration rate and other biochemical parameters remained unchanged during the study period including urinary albuminuria. Both groups were well tolerated with no serious side-effects.ConclusionsThese data indicated an additional renoprotective effect of oral supplementation with carnosine to decrease urinary TGF-β level that serves as a marker of renal injury in diabetic nephropathy.Trial registrationThai Clinical Trials, TCTR20200724002 . Retrospectively Registered 24 July 2020.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetic nephropathy, carnosine reduced urinary TGF-β versus placebo.

    In plain wordsIn patients with diabetic kidney disease, carnosine reduced urinary TGF-β compared with placebo.

    Peptide
    L-carnosine
    Outcome
    DecreaseUrinary TGF-beta
    Study

    n = 40

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Measurements

    Urinary TGF-β change
    −17.8%
    carnosine versus baseline
    Urinary TGF-β change
    16.9%
    placebo versus baseline
    Between-group P value
    < 0.05
    carnosine versus placebo

    Source sentences

    Summary
    Urinary TGF-β significantly decreased with carnosine supplement (- 17.8% of the baseline values), whereas it tended to increase with placebo (+ 16.9% of the baseline values) (between-group difference P < 0.05).
    2 context sentences
    Summary · context
    Primary outcome was decrease in urinary levels of TGF-β.
    Summary · context
    We randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetic nephropathy, blood urea nitrogen remained unchanged during treatment, including carnosine.

    In plain wordsIn patients with diabetic kidney disease, blood urea nitrogen remained unchanged during the study, including carnosine treatment.

    Peptide
    L-carnosine
    Outcome
    No significant changeBlood urea nitrogen
    Study

    n = 40

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    However, blood urea nitrogen, serum creatinine, glomerular filtration rate and other biochemical parameters remained unchanged during the study period including urinary albuminuria.
    1 context sentence
    Summary · context
    We randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetic nephropathy, serum creatinine remained unchanged during treatment, including carnosine.

    In plain wordsIn patients with diabetic kidney disease, serum creatinine remained unchanged during the study, including carnosine treatment.

    Peptide
    L-carnosine
    Outcome
    No significant changeSerum creatinine
    Study

    n = 40

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    However, blood urea nitrogen, serum creatinine, glomerular filtration rate and other biochemical parameters remained unchanged during the study period including urinary albuminuria.
    1 context sentence
    Summary · context
    We randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with diabetic nephropathy, glomerular filtration rate remained unchanged during treatment, including carnosine.

    In plain wordsIn patients with diabetic kidney disease, kidney filtration remained unchanged during the study, including carnosine treatment.

    Peptide
    L-carnosine
    Outcome
    No significant changeGlomerular filtration rate
    Study

    n = 40

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    However, blood urea nitrogen, serum creatinine, glomerular filtration rate and other biochemical parameters remained unchanged during the study period including urinary albuminuria.
    1 context sentence
    Summary · context
    We randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with diabetic nephropathy, urinary albuminuria remained unchanged during treatment, including carnosine.

    In plain wordsIn patients with diabetic kidney disease, urinary albumin remained unchanged during the study, including carnosine treatment.

    Peptide
    L-carnosine
    Outcome
    No significant changeUrinary albuminuria
    Study

    n = 40

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    However, blood urea nitrogen, serum creatinine, glomerular filtration rate and other biochemical parameters remained unchanged during the study period including urinary albuminuria.
    1 context sentence
    Summary · context
    We randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks.
  6. 06HumanRandomized controlled trialSafety outcome

    In patients with diabetic nephropathy, both carnosine and placebo were well tolerated without serious side-effects.

    In plain wordsIn patients with diabetic kidney disease, both carnosine and placebo were well tolerated without serious side effects.

    Peptide
    L-carnosine
    Outcome
    Not applicableSerious side-effects
    Study

    n = 40

    Outcome group
    Adverse events · Whole body
    Studied dose
    2 g/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Both groups were well tolerated with no serious side-effects.
    1 context sentence
    Summary · context
    We randomly assigned 40 patients with diabetic nephropathy and albuminuria 30-299 mg/day to treatment with carnosine (2 g/day) or placebo for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.